DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03714334 |
Recruitment Status :
Terminated
(Break of stock)
First Posted : October 22, 2018
Last Update Posted : April 7, 2023
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | October 16, 2018 | ||||
First Posted Date ICMJE | October 22, 2018 | ||||
Last Update Posted Date | April 7, 2023 | ||||
Actual Study Start Date ICMJE | October 16, 2018 | ||||
Actual Primary Completion Date | April 5, 2023 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Incidence of Treatment-Emergent Adverse Events after brain administration of DNX-2440. [ Time Frame: 8 weeks ] Incidence and severity of adverse effects will be collected and described
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | ||||
Official Title ICMJE | Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma | ||||
Brief Summary | Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440. | ||||
Detailed Description | After inclusion in the trial, stereotactic biopsy will be performed. In the same surgery, the experimental agent will be injected also by stereotactic system, in a different part of the lesion, in a region considered viable tumor, using a cannula especially designed for virus injection. Follow-up will include clinical visits and MRI No other treatment for the tumor will be used until progression is documented. iRANO criteria and volumetric measurement of the tumor will be used. Any further treatment after progression will be at the criteria of the treating physician |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Drug: DNX-2440 injection
DNX-2440 virus will be injected stereotactically
|
||||
Study Arms ICMJE | Experimental: DNX-2440 injection
all the patients included will be treated with the experimental agent
Intervention: Drug: DNX-2440 injection
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Terminated | ||||
Actual Enrollment ICMJE |
16 | ||||
Original Estimated Enrollment ICMJE |
24 | ||||
Actual Study Completion Date ICMJE | April 5, 2023 | ||||
Actual Primary Completion Date | April 5, 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Spain | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03714334 | ||||
Other Study ID Numbers ICMJE | D2440GBM1 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Current Responsible Party | Clinica Universidad de Navarra, Universidad de Navarra | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Clinica Universidad de Navarra, Universidad de Navarra | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | DNAtrix, Inc. | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | Clinica Universidad de Navarra, Universidad de Navarra | ||||
Verification Date | April 2023 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |